Sutro Biopharma Shares Are Trading Higher After Oppenheimer Maintained Its Outperform Rating and $10 Price Target on the Stock. The Company Recently Reported 2023 Financial Results
在奧本海默維持其跑贏大盤的評級和10美元的目標股價之後,Sutro Biopharma的股價走高。該公司最近公佈了2023年財務業績
Sutro Biopharma Shares Are Trading Higher After Oppenheimer Maintained Its Outperform Rating and $10 Price Target on the Stock. The Company Recently Reported 2023 Financial Results
在奧本海默維持其跑贏大盤的評級和10美元的目標股價之後,Sutro Biopharma的股價走高。該公司最近公佈了2023年財務業績
使用瀏覽器的分享功能,分享給你的好友吧